The evolution from early clinical observations of hypertension and proteinuria to the use of conventional biomarkers such as proteinuria and blood pressure measurement, and later to angiogenic and anti-angiogenic markers like sFlt-1, PlGF, and soluble endoglin, illustrates how the field has moved from descriptive criteria toward a more mechanistic understanding. The gene discussed is PGF; the disease is hypertensive disorder.